Price T Rowe Associates Inc. MD Lowers Holdings in Option Care Health, Inc. $OPCH

Key Points

• Price T Rowe Associates Inc. reduced its holdings in Option Care Health, Inc. by selling 10,080 shares, leaving them with approximately 1.94 million shares valued at $67.87 million.
• Insider trading activity included Director Timothy P. Sullivan purchasing 20,000 shares, increasing his stake significantly, while Director Harry M. Jansen Kraemer, Jr. also made a substantial purchase of 36,000 shares.
• Analysts have generally optimistic views on the stock, with multiple ratings citing “outperform” ratings and a price target increase to $40.00 from UBS Group.

Price T Rowe Associates Inc. MD lessened its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 0.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,941,777 shares of the company's stock after selling 10,080 shares during the period. Price T Rowe Associates Inc. MD owned approximately 1.19% of Option Care Health worth $67,866,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Brooklyn Investment Group grew its stake in shares of Option Care Health by 186.6% in the first quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock worth $42,000 after acquiring an additional 780 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in Option Care Health by 21.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after purchasing an additional 332 shares during the last quarter. Johnson Financial Group Inc. bought a new position in shares of Option Care Health in the fourth quarter worth approximately $47,000. Bessemer Group Inc. grew its holdings in shares of Option Care Health by 62.3% during the first quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock valued at $54,000 after buying an additional 599 shares during the last quarter. Finally, Wealthquest Corp bought a new stake in shares of Option Care Health during the first quarter valued at approximately $66,000. Hedge funds and other institutional investors own 98.05% of the company's stock.

Insider Activity at Option Care Health

In other news, Director Timothy P. Sullivan purchased 20,000 shares of the company's stock in a transaction on Thursday, August 21st. The stock was acquired at an average cost of $27.51 per share, for a total transaction of $550,200.00. Following the completion of the transaction, the director directly owned 49,229 shares in the company, valued at $1,354,289.79. This trade represents a 68.43% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The shares were purchased at an average price of $27.15 per share, for a total transaction of $977,400.00. Following the completion of the transaction, the director directly owned 375,390 shares in the company, valued at approximately $10,191,838.50. This trade represents a 10.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.64% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on OPCH shares. Citigroup reissued an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. Barrington Research restated an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a research note on Thursday, July 10th. Finally, JMP Securities upped their price target on shares of Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a research report on Thursday, July 31st. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $35.75.

Option Care Health Stock Performance

OPCH traded down $0.07 during midday trading on Monday, reaching $28.68. The company had a trading volume of 1,554,512 shares, compared to its average volume of 1,793,642. The business has a 50-day moving average of $29.55 and a two-hundred day moving average of $31.63. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81. Option Care Health, Inc. has a 1 year low of $21.39 and a 1 year high of $35.53. The company has a market cap of $4.65 billion, a P/E ratio of 22.94, a P/E/G ratio of 1.75 and a beta of 0.83.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.01. The firm had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The business's quarterly revenue was up 15.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.30 EPS. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities research analysts predict that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.